Breaking News
Related Searches:
5236 - 5250 of 7880 results
Prev
348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526
Next
July 22, 2009
Pharmaceutical sales were down 9% to $10.1 billion. The negative impact of foreign exchange accounted for a drop of $1.1 billion, or approximately 9%.
Read More »
July 22, 2009
Product sales were up 2% to $5.1 billion, while alliance revenue rose 54% to $179.5 million, primarily due to Erbitux revenues through the ImClone acquisition.
Read More »
July 22, 2009
Product sales were up 29% to a record $1.6 billion, driven primarily by the antiviral franchise with product sales up 26% to $1.4 billion.
Read More »
July 22, 2009
New business awards in the quarter were $266 million, representing a book-to-bill ratio of 1.2.
Read More »
July 21, 2009
Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).
Read More »
July 21, 2009
Pharmaceutical sales were down 3% in the quarter to $3.6 billion, reflecting 7% operational growth and an unfavorable impact from foreign exchange of 10%.
Read More »
July 21, 2009
Spectrum Pharmaceuticals received Fast Track designation from the FDA for apaziquone in bladder cancer.
Read More »
July 20, 2009
Orexigen Therapeutics reported that all three Phase III trials of Contrave met their co-primary endpoints for the treatment of obesity.
Read More »
July 20, 2009
Raoul Fisser was named a QP to the Quality Affairs team of SynCo Bio Partners.
Read More »
July 17, 2009
John LaHaye has been appointed to the position of vice president of business development for Catalent Pharma Solutions commercial packaging business.
Read More »
July 17, 2009
Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals for a fifth and final year, through October 2010.
Read More »
July 17, 2009
Gilead Sciences and Tibotec Pharmaceuticals, a unit of Johnson & Johnson, have entered an agreement to develop and commercialize a new fixed-dose combination of Truvada and TMC278 (rilpivirine).
Read More »
July 16, 2009
Sales in the quarter and YTD were up 8% in local currencies (lc), but were impaired by fluctuations in exchange rates.
Read More »
July 16, 2009
Growth in the quarter was driven by Tysabri sales, up 27% to $188 million, and Avonex sales, up 12% to $591 million.
Read More »
July 16, 2009
Peter Green has resigned as chairman of the board and director of Patheon, Inc., effective immediately. Mr. Green joined the board as chairman in 1996.
Read More »
5236 - 5250 of 7880 results
Prev
348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526
Next
